Drug data:

 Abstracts from the European Society for Medical Oncology Congress abstracts will be released on October 8, which could have implications for Incyte (NASDAQ:INCY), ImmunoGen (NASDAQ:IMGN), AVEO Pharmaceuticals (NASDAQ:AVEO) and Halozyme Therapeutics (NASDAQ:HALO). FDA briefing documents for Trevana's (NASDAQ:TRVN) NDA for oliceridine scheduled are due out on October 11. There is also a FDA meeting to discuss AcelRX Pharmaceutical's (NASDAQ:ACRX) Dsuvia on October 12.